Ex-Blackstone India head hunts for next star in hot IPO market
Sees significant interest in fintech, digital companies, analytics-based IT services
Mathew Cyriac is looking to take at least two companies public in India in the coming years after MTAR Technologies Pvt Ltd’s debut success.
MTAR Technologies, a precision engineering firm that Cyriac bought from Blackstone Group Inc. in 2017 when he left the private equity firm, has seen shares rise more than 60 per cent since its March debut. The listing is part of India’s red-hot initial public offerings market where companies have raised about $4 billion since the start of the year, on track for the busiest first-half since 2017, according to data compiled by Bloomberg. UBS Group AG expects a record year for first-time share sales in the country despite the coronavirus pandemic.
New Delhi: There has been increasing evidence for airborne route of transmission of SARS-CoV-2 via aerosols which is now considered to be important by international agencies WHO, REHVA, ASHRAE and by health authorities in several countries. The airbo
Management of Plus91 Technologies Pvt Ltd
Aditya Patkar, CEO and Co-Founder of Plus91 is a EMR and Hospital Technology Expert. He has been involved in implementing HIS s in 22 countries with over a 100 hospitals big and small.
Nrip Nihalani, Director and Co-Founder of Plus91 is a Health Care Technology Evangelist. He is an advocate of using technology to improve Health care globally.
Contact Address
Page Traffic
About Plus91 Technologies Pvt Ltd
Plus91 Technologies Pvt Ltd is a company registered in India and focused on Digital Health. Plus91 builds and manages the MediXcel(™) Medical Platform, which is globally used by its customers to manage the clinical information of over 34 million patients. Plus91 has customers in India, Africa, the USA, and East Asia. Plus91 Technologies Pvt Ltd and its Leadership is considered influential in the Digital Health IT space. Plus91 collaborates with local stakeholders to meaningfully improve healthcare delivery systems all over the wor
Increasing Demand of Smart Inhalers Market by 2026 | Novartis AG, BoehringerIngelheim International GmbH, Teva Pharmaceutical Industries
iCrowd Newswire
06 May 2021, 18:25 GMT+10
The drugs used in the inhalers include anti-cholinergic, glucocorticoids, insulin, and beta-agonists for the treatment and prevention of respiratory diseases such as asthma and chronic obstructive pulmonary diseases. These inhalers are termed smart inhalers, owing to the sensors attached as a clip on to the inhalers monitoring the right dose per intake and the technique used for inhaling the medication. The data acquired by the sensor is shared with the patient and healthcare professionals to track their inhaler usage
The market growth of smart inhalers can be attributed to factors such as the growing geriatric population globally and the rising number of patients suffering from respiratory diseases. According to the Office of Disease Prevention and Health Promotion, more than 25 million in the U.S. are